Caitlin E. Miron

Caitlin completed a BScH in biochemistry and a Ph.D. in supramolecular chemistry at Queen’s University. Her graduate work in the Petitjean group on targeted nucleic acid recognition was recognized by the Mitacs Award for Outstanding Innovation. In 2019, she joined a collaboration between Cyclenium Pharma and Université de Sherbrooke as a Mitacs Elevate postdoctoral fellow, driving the lead optimization of macrocyclic compounds targeting the delta opioid receptor. She is currently a postdoctoral fellow in medicinal chemistry in the Moitessier group at McGill University, where her research has recently pivoted to include the computer-guided development of drug candidates for COVID-19 therapeutics.